Schayowitz Adam

EVP, Head of R&D

Schayowitz Adam has filed 1 SEC Form 4 filing (2 transaction rows) across 1 company, with disclosures dating back to 2026. 1 of those filings fall inside the rolling window. Most recent filing: Oct 9, 2026.

On the most recent filing, Schayowitz Adam is listed as EVP, Head of R&D at Zymeworks Inc. Inside the rolling window, Schayowitz Adam reported no open-market purchases and 1 open-market sale totaling $358K in ZYME.

Companies traded

Other insiders at ZYME

Insider Buying

$0

reported purchases (SEC code P)

Insider Selling

$358K

reported sales (SEC code S)

Companies

1

in the rolling window

Source
ZYMESale$358KOct 9SEC ↗
Showing 1–1 of 1
1 / 1

Frequently asked questions

How many SEC Form 4 filings has Schayowitz Adam made?

Schayowitz Adam has filed 1 SEC Form 4 filing (2 transaction rows) across 1 company since 2026.

Which companies does Schayowitz Adam trade?

Schayowitz Adam has filed SEC Form 4 disclosures for 1 company, including ZYME.

When was Schayowitz Adam's most recent SEC Form 4 filing?

Schayowitz Adam's most recent SEC Form 4 filing on Tracefour is dated Oct 9, 2026.

What is Schayowitz Adam's job title?

On the most recent SEC Form 4 filings tracked by Tracefour, Schayowitz Adam is listed as EVP, Head of R&D.

What is Schayowitz Adam's total buy and sell value in the current window?

Inside the rolling retention window, Schayowitz Adam bought $0 and sold $358K based on SEC Form 4 filings.

What was Schayowitz Adam's largest disclosed transaction?

The largest disclosed transaction in the current window is a sale of 13,832 ZYME shares on 2026-10-09, worth $358K, per SEC Form 4 filings.